eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
boston cio of the year® orbie® awards
.
videos
.: "fremanezumab for the preventive treatment of chronic migraine."
.
.
worried about how helen was doing after doctors performed surgery on her colon the same day he was admitted, robert, whose condition stabilized, had a simple request for his nurse:
.
.
.
.
.
.
.
.